公开(公告)号：AU2018273958A1

公开(公告)日：2020-01-02

申请号：AU2018273958

申请日：2018-05-25

Applicant: LEIDOS INC

Inventor： GUTIERREZ GABRIEL M ,  KOTRAIAH VINAYAKA ,  PHARES TIMOTHY ,  PANNUCCI JAMES

IPC: C07K14/705 ,  A61K38/17

Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor "programmed death 1" (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 as well as the interaction of CTLA4 with CD86 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.

公开(公告)号：AU2022215566A9

公开(公告)日：2025-01-30

申请号：AU2022215566

申请日：2022-02-02

Applicant: GEOVAX INC ,  LEIDOS INC

Inventor： HAUSER MARY JO ,  DOMI ARBAN ,  GUTIERREZ GABRIEL ,  PANNUCCI JAMES ,  KOTRAIAH VINAYAKA ,  PHARES TIMOTHY ,  BUONTEMPO PETER ,  BROWNE CECILLE

IPC: A61K35/768 ,  C12N15/86 ,  C12N15/87 ,  C12N15/90

Abstract: The invention provides virus-based expression vectors comprising immune-checkpoint inhibitor inserts for use as effective adjuvants in enhancing T-cell priming to an antigen in a host during a vaccination regimen. In particular, the compositions described herein are novel recombinant modified vaccinia Ankara (MVA) viral constructs encoding one or more peptides which, upon administration, are expressed in a multimer conformation and subsequently cleaved and secreted from the cell. Such peptides are capable of downregulating an immune checkpoint pathway, for example, by inhibiting the activation of programmed-cell death protein 1 (PD-1), programed cell death ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), or another immune checkpoint regulator, or a combination thereof. When used in concert with the administration of an antigen during a vaccination strategy, the immune checkpoint expressing MV A viral construct provides significantly improved antigen-specific CD8+ T cell expansion, increased antigenic responses, and improved vaccination efficacy.

公开(公告)号：AU2018273958B2

公开(公告)日：2022-07-21

申请号：AU2018273958

申请日：2018-05-25

Applicant: LEIDOS INC

Inventor： GUTIERREZ GABRIEL M ,  KOTRAIAH VINAYAKA ,  PHARES TIMOTHY ,  PANNUCCI JAMES

IPC: A61K38/17 ,  C07K14/705

Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor "programmed death 1" (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 as well as the interaction of CTLA4 with CD86 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.

公开(公告)号：CA3064023A1

公开(公告)日：2018-11-29

申请号：CA3064023

申请日：2018-05-25

Applicant: LEIDOS INC

Inventor： GUTIERREZ GABRIEL M ,  KOTRAIAH VINAYAKA ,  PHARES TIMOTHY ,  PANNUCCI JAMES

IPC: C07K14/705 ,  A61K38/17

Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor "programmed death 1" (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 as well as the interaction of CTLA4 with CD86 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.